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 Abstract  
Problem: Clinical depression is a complication of stem cell transplantation. Depression can 
decrease adherence to treatment, worsen transplant outcomes, and increase mortality. At the 
University of Kansas Cancer Center (KUCC)’s Blood and Marrow Transplant (BMT) clinic, new 
patients are screened for depression using the Distress Thermometer during their first visit. This 
screening practice does not identify depression among patients after transplant. It was therefore 
important to implement standardized depression screening for post-stem cell transplant patients.  
Project Aims: The project aims of this quality improvement (QI) were: 1) to implement 
standardized screening tools (PHQ-2 and PHQ-9) for depression in this high-risk post-transplant 
patient population over 30 days, 2) to evaluate the effectiveness of PHQ-2 and PHQ-9 in 
detecting depression in post-transplant patients, and 3) to obtain feedback of the new screening 
process for depression from the medical assistants. 
Project Methods: The Plan-Do-Study-Act cycle guided this QI project. All post-stem cell 
transplant patients were screened for depression using PHQ-2 and if their scores were positive, 
they were screened with the PHQ-9. Patients screened positive on the PHQ-9 were assessed by 
their healthcare providers on the same day of their visits. Providers would initiate an 
antidepressant medication and/or refer the patient to mental health services. The following 
information was reported for a 30-day implementation period: the number of patients who were 
screened positive for depression by the PHQ-2 and PHQ-9, the number referrals to mental health 
services, and the number of antidepressants prescribed. Medical assistant feedback regarding the 
new screening process for depression were also reported.  
Findings: During the 30-day screening period, more than 200 post-transplant patients were 
screened for depression. Chart review were performed on a total of 101 randomly selected 
patients. Most of these patients (n = 100) were screened for depression using PHQ-2 and PHQ-9. 
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Nine patients had a positive PHQ-2 score (≥ 3) and received additional screening of PHQ-9. 
Eight patients were screened positive on the PHQ-9 (≥ 5) with four patients being newly 
diagnosed with depression. These four patients were either referred to mental health service 
and/or started on antidepressants. Medical assistant (MA) survey results showed that patients 
were willing to answer PHQ questions to the MA and the screening process took less than 3 
minutes to complete. Most MA’s expressed their willingness to continue PHQ screening.  
Conclusion: The new screening process for depression using PHQ-2 and PHQ-9 was effective to 
identify patients with depression. It was also useful for healthcare providers to reassess the 
treatment plans for those with existing diagnosis of depression.  It is recommended that the PHQ 
results should be automatically shown to the healthcare provider in the best practice advisory in 
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Screening for Depression in Post-Stem Cell Transplant Patients using the Patient Health 
Questionnaire (PHQ)-2 and PHQ-9 
Clinical depression is a serious complication of stem cell transplantation and needs to be 
quickly diagnosed. Patients with transplantation are known to experience depression at an even 
higher rate (25-50%) than other oncology patients (10-25%) (Cooke, Gemmill, Karvits, & Grant, 
2009; Hartung et al., 2017). The increased risk of depression for stem-cell transplant patients 
may result from lower physical quality of life during transplant, social isolation while 
neutropenic, prolonged hospital stays, and post-traumatic stress disorder (El-Jawahri et al., 
2016).  
Signs and symptoms of depression such as fatigue, loss of appetite, weight changes, 
cognitive decline, and insomnia often overlap with side effects of chemotherapy 
treatments, making depression easily overlooked by oncological healthcare providers (Smith, 
2015). Patients with depression have a decreased ability to manage their own healthcare. Most 
significantly, there is an association between depression and increased mortality (Siu, 2016). 
Depression can increase unhealthy behaviors such as smoking and alcohol use (Fann et al., 
2009). Depressive symptoms in transplant patients lowers cognitive functioning, memory, 
executive decision making, attention, and visuospatial learning (Ghazikhanian et al., 2017). 
Several studies support the association between depression and cancer-related mortality, 
with an increased risk of mortality between 19% (Pinquart & Duberstein, 2010). In another 
study, researchers 26% (Smith, 2015), and 39% (Satin, Linden, & Phillips, 2009). Research 
varies on the extent that clinical depression increases the mortality rate of oncology patients; 
however, it is consistent that depression intensifies mortality in patients with stem cell transplant. 




Patients undergoing a stem cell transplant should be routinely screened for depression to 
minimize the complications of this serious mental health disorder. Patients facing a barrage of 
somatic symptoms sometimes forget to discuss psychological changes within the limited time 
they have to speak with their healthcare providers; they may also be uncomfortable bringing up 
mental health concerns (Braamse et al., 2015).  Untreated depression may lower adherence to 
treatment and increase the risk for mortality. Routine screening could improve upon the speed of 
detection of depression in this vulnerable population potentially improving quality of life and 
minimizing adverse outcomes.  
The BMT clinic at the University of Kansas Cancer Center (KUCC) provides stem cell 
transplantation to over 300 patients annually. Currently, the Distress Thermometer (DT) is used 
to screen new patients at their first visit to assess emotional problems including depression, fear, 
nervousness, sadness, worry, or loss of interest (National Comprehensive Cancer Network 
[NCCN], 2016). However, the DT is not specifically intended to screen for depression and there 
is no standardized process for screening patients after their first visit.  
Therefore, the purpose of this QI project was to implement a standardized screening 
process for depression using the Patient Health Questionnaire (PHQ)-2 and PHQ-9 among 
patients receiving stem cell transplantation at KUCC BMT clinic. Standardized screening 
allowed for the identification of patients who suffer from depression and development of 
treatment plans.     
Background and Significance  
Depression in Transplant Patients   
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Research has shown that depression must be taken seriously as a co-morbidity in 
transplant patients since it can negatively affect patients’ adherence to treatment and increase 
mortality. The post-transplant population faces unique challenges that increase their risk for 
depression, including graft-versus-host-disease (GVHD) and neutropenic isolation (Battiwalla, 
Tichelli, & Majhail, 2016; Tecchio et al., 2013). Researchers found that transplant patients found 
25.5% had depression 6-7 weeks after transplant when only 4.2% had depression before 
transplant (Fann et al., 2009). A different study found 43.3% of patients had depression six 
months post-transplant (El-Jawahri et al., 2016). In another study of post-transplant patients, 
34% had depression one year after transplant (Vaezi, Gharib, Souri, & Ghavamzadeh, 2015).  
The standard of care treatments such as chemotherapy and radiation that transplant 
patients receive may worsen depression by producing pro-inflammatory cytokines that lower 
synaptic concentrations of serotonin and noradrenaline, neurotransmitters that have a role in 
depression (Smith, 2015). Patients with depression can have elevated levels of the hormone 
cortisol; elevated cortisol levels promote the growth of cancer cells and cause increased mortality 
(Pinquart & Duberstein, 2010). Depression is a risk factor for poor patient outcomes, and it is 
critical that transplant patients be evaluated for depression and referred to mental health services 
for treatment.    
Depression could affect transplant outcomes by reducing patient’s adherence to treatment 
regimens (Jim et al., 2016). Post-transplant patients with depression were less likely to follow 
medical recommendations after transplant for personal hygiene, prescribed exercise, neutropenic 
diets, and taking prescription medications (Mumby et al., 2012). In addition, research has shown 
that depression adversely affects transplant outcomes in the following metrics: increased hospital 
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length of stay, increased hospital readmissions, greater mortality, and slower engraftment of 
neutrophils (Jim et al., 2016; Mumby et al., 2012).  
Suicidal ideation is a rare and serious complication for 5% of patients with severe GVHD 
experience (Battiwalla et al., 2016). Risk factors for suicide ideation specifically for this 
population include patients with relapsed disease, GHVD, age older than 65 and male (Battiwalla 
et al., 2016; Tichelli et al., 2013). Although death by suicide is rare in the BMT population, their 
absolute excess rate of death by suicide is 20.91 times higher than the general population for 
both types of transplant (Battiwalla et al., 2016). Depression in transplant patients raises suicidal 
ideation by 13 times (Jim et al., 2016). Detecting depression in this critically ill population is 
central to improving quality of life, patient adherence to treatment, and decreasing mortality 
rates.  
Diagnostic Criteria of Major Depressive Disorder  
 Types of depression are differentiated in the Diagnostic and Statistical Manual of Mental 
Disorders, 5th edition (DSM-V). The DSM-V is the benchmark reference book used by mental 
health providers for descriptions, symptoms, and diagnostic criteria. Types of depression include 
major depressive disorder (MDD), persistent depressive disorder (dysthymia), disruptive mood 
dysregulation disorder, premenstrual dysphoric disorder, substance-induced depressive disorder, 
peri or post-partum depression, minor depression, and unspecified depression (American 
Psychiatric Association, 2013). The diagnostic criteria for MDD require presences of five or 
more of the following symptoms on more than half of the days or nearly every day during the 
same 2-week period with at least one of the symptoms being depressed mood or loss of interest 
or pleasure: 1) depressed or irritable mood, 2) decreased interest or pleasure, 3) significant 
weight loss or gain >5% or change in appetite, 4) change in sleep (hypersomnia or insomnia), 5) 
9 
 
change in activity (psychomotor agitation or retardation), 6) fatigue or loss of energy, 7) guilt or 
worthlessness, 8) diminished concentration or indecisiveness, and/or 9) thoughts of suicide or 
death (American Psychiatric Association, 2013). Depending on the number of total symptoms, 
the diagnosis of major depressive disorder is graded into categories of mild, moderate or severe 
(American Psychiatric Association, 2013). The most auspicious presenting sign for depression is 
loss of interest in normally pleasurable activities or anhedonia (Ward & Garlow, 2019). 
Insomnia should be investigated by the healthcare provider because waking up in the middle of 
the night or early awakening without being able to return to sleep is indicative of depression 
rather than another medical condition (Ward & Garlow, 2019). A full outline of the DSM-V 
diagnostic criteria for MDD can be found in Appendix A.  
Screening Tools for Depression 
In the literature, there are many standardized tools available to screen for depression. 
Examples of these screening tools include: NCCN’s Distress Thermometer (NCCN-DT), the 
Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT), Hospital 
Anxiety and Depression Scale (HADS), the Beck Depression Inventory (BDI), the 
Epidemiologic Studies Depression Scale Revised (CESD-R), European Organisation for 
Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), the PHQ-
9, and PHQ-2.  
NCCN Distress Thermometer (NCCN-DT). The distress thermometer was designed by 
the NCCN specifically for oncology patients (NCCN, 2016). It asks questions in yes/no format 
and assesses a patient’s overall feeling of distress in a 0 to 10 thermometer visual scale (NCCN, 
2016). The NCCN has three questions that assess for depression, sadness, or loss of interest in 
usual activities (NCCN, 2016) and three other questions that test for anxiety problems. The 
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majority of the NCCN questions, 33 of a total 40, assesses for practical problems such as 
childcare, housing, transportation, work, school, and physical symptoms like diarrhea, fevers, 
swelling, constipation, urination changes, breathing, mouth sores, mobility, nausea, pain, or 
sexual dysfunction (NCCN, 2016). A complete example of the NCCN-DT tool is in Appendix B.  
Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT). 
FACT-BMT is a quality of life tool developed for post-transplant (McQuellon et al., 1997). The 
FACT-BMT tool is a 47-question, 11-category, assessment of well-being designed to compare 
pre-transplant baseline well-being at hospital discharge and 100 days post-transplant (McQuellon 
et al., 1997). The FACT-BMT assesses for physical, emotional, functional and social well-being, 
treatment outcome, relationship with doctor, and bone marrow transplant outcome (McQuellon 
et al., 1997). The FACT-BMT tool is specific to stem cell transplant patients and does not 
primarily focus on signs and symptoms of depression.  
Hospital Anxiety and Depression Scale (HADS). The HADS has 14 questions directed 
to measuring anxiety and depression. The HADS was designed to identify depression in patients 
with chronic medical conditions and it is mediocre at detecting depression when compared to 
other available screening tools (Bjelland, Dahl, Tangen Haug, & Neckelmann, 2002).  
Beck Depression Inventory (BDI). The BDI is a patient administered inventory 
designed to measure the severity of depression (Beauvais, Martino, Walker, Roback, & Welch, 
2019). It consists of 21 multiple-choice questions. The scoring of the BDI ranges from 0 to 63 
with higher score indicative of severe depressive symptoms. The BDI results are quantitative, 
meaning that depressive symptoms which could be monitored over time (Beauvais et al., 2019). 
The BDI is not the most efficient screening tool because it may take a patient up to 10 minutes to 
complete. (Beauvais et al., 2019). 
11 
 
Center for epidemiologic studies depression scale revised (CESD-R). The CESD-R is 
an open-access tool for depression screening (Center for Innovative Public Health Research 
[CIPHR], 2019). It has 20 questions that focus on the common symptoms of MDD including 
sadness, loss of interest, appetite, sleep, thinking, concentration, fatigue, suicidal ideation, and 
guilt (CIPHR, 2019). Scoring is based on the number of days in the last two weeks the patient 
has had depressive symptoms (CIPHR, 2019). It was designed to screen undertreated populations 
including the elderly and lower socioeconomical populations, but it was not originally designated 
for oncology patients (CIPHR, 2019). The CESD-R has been such a popular depression 
screening tool that has been retested amongst oncology populations and found to be proficient 
for this specific population (Chhabria & Carnaby, 2017).  
European Organisation for Research and Treatment Quality of Life of Cancer 
Patients (EORTC QLQ-C30). The Quality of Life questionnaire EORTC QLQ-C30 has 30 
questions about depression, activities of daily living, somatic symptoms, and pain using a Likert 
scale of 1-4 (Hinz et al., 2016). This screening tool was developed to evaluate quality of life in 
oncology patients. It is copyrighted and a licensing agreement is required if used in a non-
academic setting such as clinics. It is not designed for depression and instead focuses on 
monitoring overall quality of life in oncology patients. 
Patient Health Questionnaire (PHQ)-2. The patient health questionnaire (PHQ)-2 is the 
initial two-question screening to see if patients need a full PHQ-9 depression screening. The 
PHQ-2 questions and scoring system are displayed in Appendix C. The two questions assess for 
the presence of depressed mood and loss of interest or pleasure in doing things over a 2-week 
period. The response options are 0-not at all, 1-several days, 2-more than half of the days, and 3-
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nearly every day. The scoring of PHQ-2 ranges from 0 to 6. When the score of PHQ-2 is 3 or 
greater, it is recommended to reflexively use the PHQ-9 to further evaluate for depression.     
One concern with PHQ-2 screening is that it has a low ability to discern between somatic 
symptoms of fatigue, insomnia, and lack of interest from clinical depression. This could 
contribute to a relatively low positive predictive value (25%) found in oncology patients 
(Thekkumpurath et al., 2011). However, the psychometric evaluation of the PHQ-2 strongly 
supported its validity as a brief depression screening tool (Kroenke, Spitzer, & Williams, 2003). 
Wagner and associates (2017) reported that a PHQ-2 had equivalent psychometric properties as 
PHQ-9 among oncology patients and it was more efficient than the NCCN-DT in detecting 
depressive symptoms over the course of a patient’s treatment. The use of PHQ-2 is considered 
the first step to screen for depression and its brevity makes it suitable to use in busy clinic 
settings.  
Patient Health Questionnaire (PHQ)-9. The PHQ-9 is a 9-item self-administered 
depression screening tool. The PHQ-9 assesses both somatic and affective-cognitive symptoms 
of depression. Somatic symptoms are insomnia, loss of energy, and appetite problems; affective-
cognitive symptoms are feeling depressed, self-blame, and suicidal ideation (Hinz et al., 2016). 
The PHQ-9 could help distinguish cancer treatment related somatic symptoms from depression 
specific symptoms. PHQ-9 is a unique tool because the screening questions align with the 
diagnostic criteria in the DSM-V (Thekkumpurath et al., 2011). The PHQ-9 questions are listed 
in Appendix D. The response options are 0-not at all, 1-several days, 2-more than half of the 
days, and 3-nearly every day. The scoring of PHQ-9 ranges from 0 to 27. Total scores indicate 
the level of depression; 5-9 is mild, 10-14 moderate, 15-19 moderate severe, and 20-27 is severe 
depression. See the PHQ-9 scoring system and diagnosis guide in Appendix E.  
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Research has shown that the PHQ-9 is a reliable and valid screening tool for depression 
for the general population and oncology patient (Thekkumpurath et al., 2011). For example, 
Cronbach’s alpha (internal consistency reliability index) was ≥ 0.84 when the PHQ-9 was used 
in 2,059 cancer patients (Hinz et al., 2016). The PHQ-9 has good sensitivity (93%), specificity 
(81%), positive predictive value (52%), and negative predictive value (99.4%) for major 
depressive disorder when using in oncology patients (n = 4,264) (Thekkumpurath et al., 2011).  
The literature clearly supports that the PHQ-2 and PHQ-9 are preferred screening tool for 
depression among oncology patients, when comparing to screening tools like the NCCN-DT, 
FACT-BMT, HADS, BDI, CESD-R, and the EORTC QLQ-C30.   
Screening Frequency for Depression 
The United States Preventive Service Task Force (USPSTF) recommends an annual PHQ 
screening for persons aged 12 or above (USPSTF, 2016). For any patients with depression, it is 
recommended to recheck PHQ scoring as often as every week to four weeks depending on 
treatment plan and severity of PHQ scores (New York State Department of Health, 2016). The 
ideal depression screening interval for post-transplant patients is less clear. There is no consensus 
on the screening frequency but due to the higher incidence of depression in BMT patients, more 
frequent screening is warranted. Artherholt, Hong, Berry, and Fann (2014) observed that BMT 
patients have peak depression at six weeks post-transplant and recommended at least one PHQ 
screening by the benchmark of six weeks post-transplant (Artherholt, Hong, Berry, & Fann, 
2014). Since the PHQ-2 and PHQ-9 asks about depressive symptoms in the past two weeks, 
suggesting the minimum screening interval of two weeks.  
Project Aims 
This QI project was conducted at the BMT Center of KUCC aiming to improve the 
recognition and treatment of depression in the high-risk post-transplant patient population. The 
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three specific aims of the project were: 1) to implement standardized screening tools (PHQ-2 and 
PHQ-9) for depression in this high-risk post-transplant patient population over 30 days, 2) to 
evaluate the effectiveness of PHQ-2 and PHQ-9 in detecting depression in post-transplant 
patients, and 3) to obtain feedback of the new screening process for depression from the medical 
assistants. 
Project Questions 
1. How many post-transplant patients at the BMT clinic were screened for depression over 
30 days?  
2. How many post-transplant patients at the BMT clinic were screened positive on the PHQ-
2 over 30 days? 
3. How many post-transplant patients at the BMT clinic were screened positive on the PHQ-
9 over 30 days?  
4.  How many post-transplant patients at the BMT clinic were referred to mental health 
services over 30 days?  
5. What feedback did the medical assistants have regarding the new screening process for 
depression? 
Theoretical Framework 
The Plan-Do-Study-Act (PDSA) cycle was used to guide this QI project (United States 
Department of Health and Human Services, 2008). The PDSA was developed by the Institute for 
Healthcare Improvement Model (U.S. HHS, 2008). This PDSA framework outlines how to 
implement QI projects in healthcare settings by planning the project, trying the project, 
observing the project results, and acting on the analysis of the results (U.S. HHS, 2008).  
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For this project the PDSA outlined specific implementation stages for the QI. The 
planning stage was initiated by discussing the project idea with nursing leadership at KUCC 
BMT clinic, developing the DNP project proposal and applying for Institutional Review Board 
(IRB) approval. The do stage included educating staff, adding PHQ to the document flowsheet, 
and implementing screening of patients during office visits. The study stage was the analysis of 
collected data, and evaluation of the success of the implementation of the PHQ-2 and PHQ-9 
screening tools in the BMT setting. The act stage included recommendations of modifications to 
screening and referral process based on the project findings, which is included in the Discussion 
section of this paper.  
Assumptions 
A major assumption of the project was that BMT providers were willing to use PHQ 
scores to make the diagnosis of depression. Healthcare providers at the BMT clinic may have 
avoided giving depression diagnoses for their patients due to fear of stigmatization, 
confrontations, and/or alienation of their patients; which are common barriers identified by all 
providers in diagnosing depression (Colligan, Cross-Barnet, Lloyd, & McNeely, 2018). Colligan 
et al., (2018) found that healthcare providers who are successful at screening for depression, had 
the ability to establish trusting relationships with patients by using common language instead of 
jargon (Colligan et al., 2018). For that reason, BMT providers were advised to avoid jargon 
when assessing patients who are screened positive on PHQ-9.  
A second potential limitation in screening patients for depression was that patients may 
refuse screening for mental health symptoms. In a previous study of psychological interventions 
for transplant patients only 61.1% of patients agreed to screening; study participants cited a lack 
of energy and lack of interest in psychological problems as the primary reasons for refusal 
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(Braamse et al., 2015). Patients may also have incentive to under-report symptoms to avoid the 
stigma of mental illness. This project tried to avoid this potential pitfall of non-participation by 
having a short-scripted introduction before PHQ questions were asked. For example, the medical 
assistant staff would say “Now I would like to ask you some questions about your mood, please 
consider the questions carefully. This may help your nurse practitioner or physician improve 
your care”.  
A final consideration was given to how to effectively screen for depression without 
wasting clinical time. In support of the plan, a study of 342 oncology patients found the PHQ-9 
screening to be generally feasible to include in a patient exam by adding the screening to the 
computerized data collected at a regular patient visit along with pain score and vital signs (Fann 
et al., 2009). Only 50% of patients required a full PHQ-9 screening (Fann et al., 2009), which 
only takes an estimated 2.5 minutes for most patients (Thekkumpurath et al., 2011; Fann et al., 
2009). Using the PHQ-2 as the first step of screening can minimize the use of clinical time as 
only those screened positive will require PHD-9 (Wagner et al., 2017).  
Project Methodology 
Design 
The purpose of this quality improvement (QI) project was to implement a standardized 
depression screening process in outpatient post-BMT patients using the PHQ-2 and PHQ-9 for 
30 days. The Project Director educated all outpatient staff about how to administer the PHQ 
depression screening tools by emails and presentation at department staff meetings in May 2019. 
Education about the incidence of depression and the impact of depression on patient outcomes 
was discussed before medical assistants were given education on how to perform the screening 
using PHQ-2 and PHQ-9. When this project was implemented from June 10 to July 7, 2019, all 
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clinic staff were given additional motivation to complete the screening by educating them about 
the complications of depression in the BMT population.  
The Patient Health Questionnaire (PHQ) was built into Epic, the current electronic health 
record (EHR) that the University of Kansas Health System uses. The BMT medical assistant 
staff were trained to enter the scores of PHQ-2 and PHQ-9 in EHR for all post-transplant patients 
in the clinic for outpatient provider visits. A laminated copy of the PHQ-2 and PHQ-9 was kept 
in each exam and treatment room for patients to follow along as the medical assistant read aloud 
the PHQ questions to the patient. This was intended to reduce the screening time by allowing 
patients to read the questions and visualize the Likert scoring system. Patients that had positive 
PHQ-2 screenings were further screened using PHQ-9. Medical staff reported positive scores to 
the healthcare provider seeing the patient that day.  
Setting 
This QI project was conducted at the BMT clinic in the University of Kansas Health 
System. It is an outpatient clinical unit in the Bloch Cancer Care Pavilion, in Westwood, Kansas. 
Patients are referred to BMT from community oncologists for two main types of stem cell 
transplant: autologous when they receive their own cells and allogeneic when they receive 
another person’s stem cells. An average of 60-100 patients are seen each weekday in provider 
visits. The support letter for this project from clinical leadership can be found in Appendix F. 
Sample 
   The eligible patient participants for the project included all the patients who have 
previously undergone stem cell transplant and have scheduled visits with either advanced 
practice registered nurses or physicians during the 30-day implementation period. These post-
transplant patients originally had life-threatening primary oncological diagnoses such as multiple 
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myeloma, acute myeloma leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, 
diffuse large B cell lymphoma, mantle cell lymphoma, Non-Hodgkin’s Lymphoma, aplastic 
anemia, or sickle cell anemia. Subjects were limited to English and Spanish speakers due to the 
PHQ being freely available in those languages. Subjects with known learning disabilities or 
cognitive disorders were excluded.  
Procedures 
The PHQ screening questions (PHQ-2 and PHQ-9) were completed by the patient under 
the direction of the medical assistant during the rooming process for 30 days. The Epic EHR has 
the PHQ built into the document flowsheet. The Epic computer software automatically 
calculated the patients’ total scores as the staff member entered the patient’s answers. All post-
transplant patients were initially screened with the PHQ-2 tool.  
Initial screening with PHQ-2. The initial screening PHQ-2 (Appendix C) includes two 
questions of a) over that last two weeks, how often have you been bothered by the following 
problems: feeling down, depressed, irritable, or hopeless? and b) had little interest or pleasure in 
doing things? (Siu, 2016). The subject rated their responses on a Likert scale of not at all (0), 
several days (1), more than half the days (2), or nearly every day (3) (Siu, 2016). A total score of 
3 or more on the PHQ-2 indicates positive screening and requires further evaluation using the 
PHQ-9.  
Further evaluation with PHQ-9. The PHQ-9 (Appendix D) tool contains nine questions 
that ask if the subject in the last two weeks has felt a) little pleasure or interest in doing things, b) 
feeling down, depressed or holes, c) sleeping too little or too much, d) feeling tired or having 
little energy, e) poor appetite or overeating, f) feeling bad about yourself or that you are a failure 
or have let your family down, g) concentration problems, h) moving or speaking so slowly that 
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other people could have noticed or being so fidgety or restless that you have been moving around 
a lot more than usual, and i) thoughts that you would be better off dead or hurting yourself in 
some way (Siu, 2016). These nine questions are scored on a Likert scale of not at all (0), several 
days (1), more than half the days (2), or nearly every day (3). The total PHQ-9 score can range 
from 0 to 27. A PHQ-9 score of greater than 4 is positive screening. Higher PHQ-9 score 
indicates the severity of depression (mild: 5-9; moderate: 10-14; moderately severe: 15-19; and 
severe: 20-27) (Appendix E).    
A positive screening on the PHQ-9 (a score > 4) was reported to the healthcare providers 
(APRN or physicians) who were seeing the patients that day. Treatment considerations depended 
on the severity of depression according to the PHQ-9 scores. For a patient with a PHQ-9 score of 
5-9 (mild depression), the healthcare provider seeing the patient that day was informed. While 
antidepressant treatment may not be indicated, these patients were rescreened about two weeks 
later on their return visits. Patients that score between 10-27 were evaluated for major depressive 
disorder based on DSM-V criteria (Fann et al., 2009). A depressed mood or a lack of interest or 
pleasure in doing things are two cardinal symptoms of depression, which must be endorsed by a 
patient for a positive PHQ-9 (Siu, 2016). Patients with PHQ-9 scores for moderate (10-14) or 
moderately severe depression (15-19) were offered to start an antidepressant medication and/or a 
referral to mental health services. Patients with PHQ-9 score of severely depressed (20-27) were 
offered both initiation of an antidepressant and emergent referral to mental health provider. The 
healthcare provider seeing the patient the same day of the PHQ screening placed the orders for 
antidepressant medication and/or ambulatory referral to mental health provider.  
Patients with positive PHQ screenings required a skillful evaluation by a healthcare 
provider to receive a diagnosis of depression and to develop a treatment plan using a shared 
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decision-making model. When patients screened positive for PHQ but are not seen regularly at 
the BMT clinic, their primary care provider were notified of the score and the need for a follow-
up assessment. When PHQ-9 scores were above 4 and/or the patient had a current diagnosis of 
depression, the patient was rescreened about two weeks later at their next scheduled visit. 
Patients whom were not diagnosed with depression they were re-screened at their next scheduled 
appointment. 
Data Collection  
 The main outcomes of the project were: 1) number of PHQ screenings completed on 
post-transplant patient visits during the 30-day period, 2) number of patients screened positive 
for depression (PHQ-2 and PHQ-9), and 3) number of patients who were referred for 
psychologist services. Data were collected by reviewing the EHR. The Project Director randomly 
selected 100 EHRs of post-transplant patients who were seen during June 3 through July 7th, 
2019 after 30 days of implementation of PHQ screening. A sample size of 100 patients was 
desired to ensure an adequate data set to evaluate our project questions without being too large of 
an amount of data to be able to see patterns in the results. 
A data collection spreadsheet was used to record data (Appendix H). Data collected from 
post PHQ screening implementation included transplant type, PHQ-2 and if available PHQ-9 
scores, referrals to psychologist, antidepressant prescriptions, and depression diagnosis. Basic 
demographic information such as age, gender, and ethnicity were also collected. Patients who did 
not complete PHQ screening questions were also recorded in order to consider how many post-
transplant patients have benefited from depression screening. Patient’s transplant type was found 
in provider notes. PHQ scores and dates were found the EHR under document flowchart. 
Depression diagnosis was found on the patient’s problem list on their snapshot. Referrals to 
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psychology or palliative care were found under referrals tab on the EHR chart review. 
Prescriptions for antidepressants were found on the patient’s medication list.  
Finally, the sustainability of the new screening process for depression was gauged by the 
MA’s opinions on the screening. All medical assistants (n = 11) at KUCC BMT clinic were 
invited to complete a short Medical Assistant Post Implementation Survey anonymously after the 
30-day implementation period in July 2019. The survey focused on the feedback from the MA’s 
regarding time to perform the screening, patients’ cooperation in screening, and their willingness 
to continue screenings in the future (Appendix G). The survey also had a free text space for 
additional comments. The survey was developed and distributed using SurveyMonkey® website.  
Evaluation  
Descriptive statistics (mean and standard deviation [SD]) were calculated to describe the 
continuous variables including age, PHQ-2 and PHQ-9 scores. Frequency and percentage were 
used to report categorical variables such as gender, race/ethnicity transplant types, number of 
patients who completed PHQ-2, number of patients screened positive for PHQ-2 and completed 
the PHQ-9, number of patients screened positive for PHQ-9. The number of post-transplant 
patients who were referred to mental health services and/or started on antidepressants were also 
reported. It was originally planned to compare differences in the means of PHQ-9 scores by the 
two different transplant types using the t-test. However, this was not performed due to small 
subsample size. Descriptive statistics (number and frequency) were used to report results from 
Medical Assistant Post Implementation Survey. Additional narrative comments were 
summarized and reported.    
Human Subject Protection   
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An application for determination of this QI project was submitted and approved by the 
Institutional Review Board (IRB) at the University of Kansas Medical Center in May 2019. The 
project was initiated in May 2019 when the IRB approval was received. Informed consent was 
not sought from patients as this QI was part of normal health care operations at the KUCC BMT 
clinic. Patient protected health information (PHI) was only accessed when the Project Director 
opened the patients’ EHR to collect data pertinent to the evaluation of the project. Only non-PHI 
data was collected to measure the change in practice as a result of the QI project. Standard 
confidentially of patient visits and diagnoses was maintained to staff directly involved in the 
patient’s care. 
Patients were immediately de-identified in data collection phase in order to protect their 
privacy. The Project Director accessed the EHR after the implementation period was completed 
and collected all necessary information from the chart in a single viewing and record data 
without unique patient identifiers. Name, date of birth, and medical record number were 
excluded. The de-identified data were stored in an electronic format on a password protected 
computer with antiviral software. Only aggregated data were reported in this final report of the 
project findings.  
Results 
Characteristics of Project Participants 
More than 200 post-transplant patients were screened for depression using PHQ-2 and 
PHQ-9 during the 30-day implementation period. A total of 101 EHRs of these patients were 
randomly selected to retrieve demographic information and the PHQ screening results. Most 
patients (n = 100, 99%) were willing to be screened for depression with only one (1%) who 
declined. The mean age of screened patients was 54.2 years old and over half (54%) were male. 
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Most screened patients (n = 87, 88%) were European American, followed by Hispanic (n = 7, 
7%), African American (n = 4, 4%), and Asian (n = 2, 2%) (Figure 1). For the types of 
transplant, 26 patients had a history of autologous stem cell transplant (25.7%) and 75 had a 
history of allogeneic stem cell transplant (74.3%). 
Positive PHQ-2 and PHQ-9 Screening 
The mean PHQ-2 score for all 100 screened patients was 0.82 (SD = 1.20). There were 
only nine patients (9%) who scored 3 or 4 on their PHQ-2 and required a subsequent PHQ-9 
screening (Figure 2). Of these nine patients who had completed the PHQ-9, the mean score of 
PHQ-9 was 10.11 (SD = 3.70). Eight of the 9 patients were screened positive on PHQ-9 (89%). 
Among the eight positive PHQ-9 screening, three (37.5%) had mild depression (a PHQ-9 score 
of 5 - 9), four (50%) had moderate depression (a PHQ-9 score of 10 - 14), and one (12.5%) had 
moderately severe depression (a PHQ-9 score of 15 - 19). None of the eight patients had severe 
depression, PHQ score of 20 - 27. Distribution of depression by severity and transplant types 
among the eight patients screened positive by PHQ-9 were presented in Figure 3.  
Evaluating the eight patients who screened positive on the PHQ-9, seven had allogeneic 
transplant and one had autologous transplant. Among the allogeneic patients who screened 
positive on the PHQ-9, three had mild depression, three had moderate depression, and one had 
moderately severe depression (Figure 3). The one autologous transplant patient was screened 
positive for moderate depression on PHQ-9 (Figure 3). Since there were only nine patients who 
required PHQ-9 screening with only one being the autologous transplant, t-test was not 
performed to compare PHQ-9 scores by transplant type as originally planned. Of the total 17 
newly or existing diagnoses of depression in the project sample, 16 of those patients had 
allogeneic stem cell transplant history.  
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Four patients (4%) out of the 100 were newly screened positive for depression during this 
implementation period. There were 13 (13%) patients who had existing depression diagnoses 
based on EHR review. However, nine out of 13 with pre-existing diagnoses of depression did not 
screen positive for active depression symptoms with the PHQ tools. All patients with pre-
existing diagnosis of depression (n = 13) had received allogeneic stem cell transplant. None of 
the autologous stem cell transplant patients had existing diagnoses of depression.  
Treatment Plans for Positive PHQ-9 Screening  
The review of treatment plans for patients whom screened positive on PHQ-9 showed 
four patients had existing referrals to psychologists and three patients had new referrals placed 
after screening positive on the PHQ-9 (Figure 4). However, one allogeneic patient with newly 
positive screening on PHQ-9 was not referred as recommended. Eight patients had existing 
antidepressant prescriptions and three new antidepressant prescriptions were written after 
positive PHQ-9 screening. One autologous patient screening positive for depression declined an 
antidepressant (7.14%) (Figure 5). One positive PHQ allogeneic patient was not offered an 
antidepressant (7.14%) (Figure 5). Almost all patients on existing antidepressant prescriptions or 
offered new prescriptions had allogeneic transplant histories (n = 12, 85.72%).  
Feedback from Medical Assistants 
 The Medical Assistant Post Implementation survey was sent via emails after the 30-day 
trial period in July 2019. All 11 medical assistants were invited to complete the survey. A total of 
7 MAs responded with a response rate of 64%. One MA was on family medical leave and was 
not able to respond. Another three MA’s chose not to respond. Results of feedback from Medical 
Assistants were summarized in Figure 6. The first question asks, “Did the PHQ-2 and PHQ-9 
surveys take you less than 3 minutes to complete on average?”. Majority of MAs (n = 6, 85.7%) 
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responded “yes”. All MAs (n = 7, 100%) found that patients were willing to answer PHQ 
questions during the rooming process. Majority of MAs (n = 6, 85.7%) expressed their 
willingness to continue the screening process. Three MAs provided narratives in the comments 
section. However, only one comment seemed to be applicable to the project (“Question 1 people 
tend to struggle with so probably look into rewording it”). It was unclear which questionnaire 
(PHQ-2 or PHQ-9 or the medical assistant survey itself) the respondent with this comment 
referred to.  
Discussion 
This quality improvement project was to implement a new screening process for 
depression using PHQ-2 and PHQ-9 among patients receiving post stem cell transplants at the 
BMT Center of KUCC. During the 30-day implementation period, most patients (n = 100, 99%) 
participated in the new screening for depression among the 101 charts reviewed. One patient 
declined screening. The participation rate was much higher than anticipated. In a previous study 
of transplant patients, only 61.1% of patients agreed to screening due to lack of energy and lack 
of interest (Braamse et al., 2015). The new screening process identified a total of nine patients 
(9%) with a positive PHQ-2 score (≥ 3) and eight patients (8%) with a positive PHQ-9 score (≥ 
5). Four of the eight patients screened positive on the PHQ-9 were newly identified and the other 
four had an existing diagnosis of depression on their EHR. There were additional nine patients 
who had an existing diagnosis of depression but were screened negative during the 30-day 
screening period. Therefore, the proportion of patients with depression (either an existing 
diagnosis of depression or screened positive on the PHQ-9) were 17% among the 100 screened 
patients. This was relatively lower than the reported 25-50% among transplant patient population 
(Cooke, Gemmill, Karvits, & Grant, 2009). This could be due to the short screening period (30 
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days) and not allowing for a second cycle of quality improvement plan-do-study-act to reinforce 
process changes and make improvements in staff education.  
All patients in the sample with a pre-existing history of depression (n =13) had received 
allogeneic transplants. Similarly, most patients who newly screened positive for depression using 
the PHQ-9 (n = 7, 87.5%) had a history of allogeneic transplant. It appears that in this project 
sample, patients with allogeneic transplant had a much higher incidence of depression than those 
with the autologous transplant. This was not consistent with a previous study where it was 
reported that autologous patients (n = 30) had psychological distress scores than allogeneic 
patients (n = 60) and higher PHQ-9 scores by 2.45 on average (El-Jawahri et al., 2014). This 
could be explained by that the autologous patients typically had more lifetime cycles of 
chemotherapy due to their primary oncology disease and lower quality of life going into 
transplant (El-Jawahri et al., 2014). It is unfortunate that due to a too small sample size for the 
autologous patients requiring PHQ-9 test that a t-test was not performed to compare group 
differences in PHQ-9 scores by these two transplant types. Future investigation is warranted to 
compare KU BMT transplant types to nationwide transplant patients.   
Healthcare providers in BMT seemed ready to use PHQ-9 scoring to diagnose depression 
and to reassess exiting depression diagnoses. All four patients who were newly screened positive 
on the PHQ-9 were given diagnosis of depression and offered antidepressants or referrals to 
mental health specialists. All three patients with pre-existing depression diagnoses and a positive 
PHQ-9 score were either already on antidepressants or had a previous mental health referral. A 
missed opportunity for depression treatment was identified for one allogenic patient with 
moderate depression (PHQ-9 score 13) who was not referred to a mental health specialist, but 
was given a new prescription for an antidepressant. Another allogeneic patient with moderate 
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depression (PHQ-9 score 14) was not offered an antidepressant but had an existing referral to 
mental health specialist. PHQ scoring guidance recommendations patients who have moderate 
depression (a PHQ-9 score of 10-14) could benefit from both mental health referrals and 
antidepressant based on the duration of patients’ symptoms and functional impairment. Perhaps 
these patients did not need both antidepressant and referral based on the clinical evaluation of 
their depression but no documentation of this was discussed in the progress note.  
The significance of this QI project is three-fold. First, this screening process supported 
the efficient screening, diagnosing, and provider reassessment of existing depression with a 
quantitative metric for depressive symptoms. It is significant that most patients screened (n = 92) 
had negative PHQ-2 scores. Depression was newly identified in four patients (4%) during the 
implementation phase of this project. Four patients with existing depression had positive PHQ-9 
scores that were reported to the healthcare provider seeing the patient that day. The PHQ-9 
results greatly assist the healthcare provider in making a new diagnosis of depression as it 
addresses all the DSM-V criteria. The healthcare provider merely needed to confirm the PHQ-9 
results with the patient and make the diagnosis. Nurse practitioners should lead this practice 
change to incorporate depression assessments into cancer treatment. As providers strive to 
practice based upon evidence-based findings, adequate treatment of depression proves to be an 
important part of care for transplant patients.  
Second, the PHQ tool gives a quantitative number for healthcare providers to reassess 
existing depression diagnoses in terms of mild, moderate, moderately severe, and severe and 
helps determine if depression is active or in remission. The PHQ tool does assist healthcare 
providers to make informed decisions in modifying a patient’s depression treatment.  
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Third, the PHQ-2 and PHQ-9 is an efficient screening tool for depression. Most surveyed 
medical assistants (n = 6, 85.71%) reported that the screening took less than three minutes and 
they were willing to continue the screening process in their rooming workflow. Despite the 
efficiency, a concern of use of clinical staff time has been a perceived barrier. Continuing to use 
this screening tool has faced objection due to overall time spent screening patients for fall risk, 
pain, fatigue, suicide ideation, and caregiver distress. All these routine screenings add time to the 
rooming process but not as much as the perceived effort. In actual timed trials it only takes a 
Medical Assistant 2.5 minutes, on average, to complete the entire PHQ-9 (Thekkumpurath et al., 
2011; Fann et al., 2009).   
Limitations 
Several limitations of the project are worth noting. One limitation was that more 
allogeneic patients (n = 75) were screened than autologous (n = 26) in this project. This skewed 
screening of more allogeneic patients highlights a process limitation in the way the project was 
designed. The project consisted of screening patients for depression when they arrived for 
scheduled appointments. The autologous stem cell transplant patients that were transferred back 
to their primary oncologist after transplant for monitoring and maintenance chemotherapy were 
not screened for depression under this system. This screening practice also would not have 
captured allogeneic patients that did not show, were hospitalized, had passed away, or 
rescheduled were not screened with the PHQ tool. Patients were not captured in the data 
collection could theoretically have higher rates of depression leading to more frequent 
hospitalizations, higher mortality, lack of adherence to treatment plans hence missed or canceled 
appointments. Depression is known to reduce patient’s adherence to treatment regimens and 
increase mortality (Jim et al., 2016). In addition, the implementation period of this new screening 
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process was relatively short (30 days) and only had one plan-do-study-act cycle. A longer 
implementation period with repeated quality improvement cycles may have screened more 
patients and potentially identified more patients with positive PHQ-2 and PHQ-9 scores.  
Recommendations for Practice 
There are several recommendations to make from this QI project. The first 
recommendation is to make PHQ scoring results more accessible to healthcare providers. They 
are currently either looking up the score under the document flowsheet or getting a verbal report 
from the medical assistant. This reporting process has potential for errors in reporting. The Epic 
EHR software is capable of automatically populating PHQ scores to the providers’ screen in their 
treatment plan as a pop up called “a best practice advisory”. The BMT clinic does not currently 
have this function selected for the healthcare providers. The Project Director investigated adding 
this function to the providers preferences and the Operations Analysist (computer specialist for 
BMT) is making this change in August 2019.  
The second recommendation is to automatically screen patients with the PHQ-2 and the 
PHQ-9 through the MyChart patient chart interface. Perhaps in the future, MyChart could notify 
patients when screenings are needed, send them the questionnaire electronically, and then 
patients could complete the screenings on MyChart. The screening results could be sent to a 
providers in-basket if follow-up is required. Previous studies have shown that patients can 
complete the PHQ-9 on a touchscreen themselves on average in 2 minutes (Fann et al., 2009). 
The benefit would be to reduce the time required to room patients and to capture patients without 
provider visits.  
The third recommendation is to further investigate the relationship between depression 
and stem cell transplant. Limited research has been done to see if treating depression effectively 
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in transplant patients would lower mortality, hospitalizations, and increase adherence to 
treatment. It is not clear if there is a preferred method of mental health treatment or preferred 
antidepressant more effective for stem cell transplant patients with depression. More research 
should be done on if any prevention measures implemented before transplant could limit the 
adverse outcomes of depression.  
Conclusion 
 Depression is a serious and often untreated complication of stem cell transplant. This QI 
project aimed to implement a new screening process for depression using the PHQ-2 and the 
PHQ-9 in the BMT clinic of the KUCC. The results of this QI project showed that it was 
effective to use a standardized PHQ tool to screen transplant patients for depression. 
Implementing this screening process helped detect depression in four new patients. The PHQ-9 
scores were critical for the reassessment of existing depression in four patients with existing 
depression and positive PHQ-9 scores. The PHQ tool seems suitable as a depression screening 
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Appendix A:  
Diagnostic Criteria for Major Depressive Disorder and Depressive Episode 
 
Note: City of Palo Alto, (2019). Project Safety Net’s Diagnostic Criteria for Major Depressive 


















Appendix B:  
The NCCN’s Distress Thermometer Scale 
 
Note: National Comprehensive Cancer Network, (2018). NCCN Distress Thermometer and 













Appendix C:  
Patient Health Questionnaire (PHQ) - 2 
 
 




Appendix D:  
Patient Health Questionnaire (PHQ) - 9
 








Appendix E:  
Patient Health Questionnaire (PHQ)-9 Scoring System and Diagnosis Guide 
 
Note: PsychCongress.com, (2019). Instruction Manual: Instructions for Patient Health 
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Appendix G:  
Medical Assistant Post Implementation Survey 
Thank you for your assistance in implementing the new screening process for depression among 
post stem cell transplant patients. The purpose of this survey is to obtain your feedback regarding 
the implantation of this new process.  
1. Did the PHQ-2 and PHQ-9 surveys take you less than 3 minutes to complete on average? 
a. -Yes 
b. -No 
2. Were most patients willing to answer the PHQ questions for you? 
a. -Yes 
b. -No 
3. Would you be willing to continue this screening process?  
a. -Yes 
b. -No 
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Appendix I:  



























EthnicityHispanic Asian Cauasian Black Gender Female Male Ages 18-38 39-58 59-68 69-100
Series1 7 2 87 4 46 54 17 38 33 13
CHARACTERISTICS OF PROJECT PARTICIPANTS
46 
 
Appendix J:  




























1 2 3 4 5 6 7 8 9
PHQ-9 SCORES FOR ALL PATIENTS 
WITH POSITIVE PHQ-2 SCORES








Appendix K:  








Allogeneic 3 3 1 0














Appendix L:  




Existing Psychologist Referral 4
New Psychologist Referral 1 2
Declined
Not offered 1
REFERRALS TO PSYCHOLOGIST 




Appendix M:  
Figure 5. Transplant Type and Antidepressant Prescriptions amongst PHQ-9 Positive Patients 
  
Autologous Allogeneic
On Existing Antidepressant 0 3
Started Antidepressant 0 3
Declined Antidepressant 1 0
Not Offered Antidepressant 0 1
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Question One: Did the PHQ-2 and
PHQ-9 surveys take you less than 3
minutes on average?
Question Two: Were most patients
willing to answer the PHQ questions
for you?
Question Three: Would you be
willing to continue this screening
process?
MEDICAL ASSISTANT SURVEY RESPONSES
Yes No
